Search

Your search keyword '"Segui E"' showing total 24 results
Start Over Author "Segui E" Publication Type Academic Journals
24 results on '"Segui E"'

1. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

Author

Schettini, F., Nucera, S., Brasó-Maristany, F., De Santo, I., Pascual, T., Bergamino, M., Galván, P., Conte, B., Seguí, E., García Fructuoso, I., Gómez Bravo, R., Rivera, P., Rodríguez, A.B., Martínez-Sáez, O., Ganau, S., Sanfeliu, E., González-Farre, B., Vidal Losada, M.J., Adamo, B., Cebrecos, I., Mension, E., Oses, G., Jares, P., Vidal-Sicart, S., Mollà, M., Muñoz, M., and Prat, A.

Published
2024
Full Text
View/download PDF

5. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Author

Paré, L., Pascual, T., Seguí, E., Teixidó, C., Gonzalez-Cao, M., Galván, P., Rodríguez, A., González, B., Cuatrecasas, M., Pineda, E., Torné, A., Crespo, G., Martin-Algarra, S., Pérez-Ruiz, E., Reig, Ò, Viladot, M., Font, C., Adamo, B., Vidal, M., Gaba, L., Muñoz, M., Victoria, I., Ruiz, G., Viñolas, N., Mellado, B., Maurel, J., Garcia-Corbacho, J., Molina-Vila, M Á, Juan, M., Llovet, J.M., Reguart, N., Arance, A., and Prat, A.

Published
2018
Full Text
View/download PDF

10. 1481P Expression of ERBB2 and PD1 mRNA in advanced gastric cancer

Author

Pesántez, D., Brasó-Maristany, F., Esposito, F., Oberoi, H.K., Oliveres, H., Pascual, T., Cuatrecasas, M., Teixido Febrero, C., Sanfeliu, E., Laguna, J.C., Seguí, E., Pérez, A., Martínez, D., Guerrero, J., López, S., Fernández-Esparrach, G., Momblán, D., Fillat, C., Prat, A., and Sauri, T.

Published
2020
Full Text
View/download PDF

11. 1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score

Author

Seguí, E., Auclin, E., Casadevall, D., Aguilar-Company, J., Rodriguez, M., Epaillard, N., Tagliamento, M., Pilotto, S., López-Castro, R., Mielgo, X., Urbano, C., Rodríguez, A., García-Illescas, D., Bluthgen, M.V., Masfarré, L., Oliveres, H., Minatta, J.N., Marco-Hernández, J., Prat, A., and Mezquita, L.

Published
2020
Full Text
View/download PDF

16. Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.

Author

Martínez-Vila C, Laguna JC, Segui E, Ruiz G, Aya Moreno F, Fernandez-Morales LM, Giner Joaquim J, Padrosa J, Fernandez L, Gaba L, Victoria I, and Arance Fernandez AM

Subjects
Biomarkers, Tumor, Clinical Decision-Making, Disease Management, Disease Susceptibility, Female, Humans, Immune Checkpoint Inhibitors therapeutic use, Male, Melanoma diagnosis, Melanoma drug therapy, Melanoma etiology, Middle Aged, Molecular Targeted Therapy methods, Mutation, Neoplasm Grading, Neoplasm Staging, Treatment Outcome, Encephalitis diagnosis, Encephalitis etiology, Immune Checkpoint Inhibitors adverse effects, Melanoma complications, Molecular Targeted Therapy adverse effects
Abstract

Since the approval of immune checkpoint anti-programmed cell death protein 1 antibodies (pembrolizumab and nivolumab) and anti-cytotoxic T-lymphocyte-associated protein 4 (ipilimumab) in combination or monotherapy, significant advances have been made in the treatment of metastatic melanoma. The nonspecific immune stimulation resulting from these drugs can case a wide range of side effects in many organs including the nervous system, named immune-related adverse events. Few immune-related encephalitis associated with these antibodies have been described in the literature. It is a rare complication (<1% of the total of immune-related adverse events) but it can be fatal if not diagnosed and treated on time. We describe 3 cases of patients with melanoma, which were treated with a combination of ipilimumab-nivolumab (case 1), ipilimumab monotherapy (case 2), and nivolumab monotherapy (case 3), who developed an encephalitis which was related to immune checkpoint therapy., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

17. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.

Author

Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Maconi A, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Carbo A, Bruna R, Benafif S, Marrari A, Wuerstlein R, Carmona-Garcia MC, Chopra N, Tondini C, Mirallas O, Tovazzi V, Betti M, Provenzano S, Fotia V, Cruz CA, Dalla Pria A, D'Avanzo F, Evans JS, Saoudi-Gonzalez N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, Patriarca A, Garcia-Illescas D, Reyes R, Dileo P, Sharkey R, Wong YNS, Ferrante D, Marco-Hernandez J, Sureda A, Maluquer C, Ruiz-Camps I, Gaidano G, Rimassa L, Chiudinelli L, Izuzquiza M, Cabirta A, Franchi M, Santoro A, Prat A, Tabernero J, and Gennari A

Abstract

The SARS-Cov-2 pandemic significantly impacted on oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncological features on severity and mortality from Covid-19 and little guidance as to the role of anti-cancer and anti-Covid-19 therapy in this population. In a multi-center study of 890 cancer patients with confirmed Covid-19 we demonstrated a worsening gradient of mortality from breast cancer to haematological malignancies and showed that male gender, older age, and number of co-morbidities identifies a subset of patients with significantly worse mortality rates from Covid-19. Provision of chemotherapy, targeted therapy and immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk-stratification of patients and support further research into emerging anti-Covid-19 therapeutics in SARS-Cov-2 infected cancer patients., (Copyright ©2020, American Association for Cancer Research.)

Published
2020
Full Text
View/download PDF

18. [Follow-up of patients treated by VKA: Interest of a pharmaceutical link between the hospital and the retail pharmacies].

Author

Bidon D, Lecoeur A, Segui E, Seguette N, Le Mercier F, and Bauler S

Subjects
Aged, Aged, 80 and over, Drug-Related Side Effects and Adverse Reactions epidemiology, Female, Follow-Up Studies, France epidemiology, Humans, Male, Middle Aged, Patient Education as Topic, Pharmacies, Pharmacy Service, Hospital, Anticoagulants adverse effects, Vitamin K antagonists & inhibitors
Abstract

Vitamin K antagonists (VKA) are used by 1,7% of the French population. Patient education and monitoring can decrease the number of iatrogenic hospitalizations due to VKA. We assessed the impact of a communication between hospital and retail pharmacists about patient's knowledge on VKA. The aim of our study has been to evaluate the value added by the link between the hospital pharmacist and the community pharmacist on the follow-up of patients treated by vitamin K antagonist. Patient information about VKA treatment is offered to inpatients in our hospital. An information form is filled for each patient treated by VKA. Patient's knowledge is assessed on the document (Name of VKA, cause of treatment, monitoring, risks of overdose, compliance…). This form is sent to the community pharmacist after the training when the patient leaves the hospital (by fax or by email). The form is sent back by the community pharmacist after the second training. Sixty-eight patients received the training, 48 forms have been sent to the retail pharmacists and 43 forms have been sent back to the hospital. Seven retail pharmacists replied spontaneously. Twenty-eight patients increased their knowledge (in average+21%) and 12 patients stabilized their knowledge. The best-known concepts were the INR target, the time of drug intake, the risks of overdose and the information of the family. The improvement of knowledge is significant for the name of VKA, the cause of treatment, efficacy assessment and signs of overdose. The implementation of a communication between the hospital and the retail pharmacies is time-consuming but the follow-up of those patients seems essential to keep a good knowledge., (Copyright © 2016 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.)

Published
2017
Full Text
View/download PDF

19. [Postpartum hemolytic uremic syndrome: a rare entity and a treatment challenge].

Author

Alsina Segui E, Martín Conde ML, Craver Hospital L, and Fernández Giráldez E

Subjects
Adult, Female, Humans, Hemolytic-Uremic Syndrome diagnosis, Hemolytic-Uremic Syndrome therapy, Puerperal Disorders diagnosis, Puerperal Disorders therapy
Abstract

Hemolytic uremic syndrome (HUS) is a rare entity that in 7% of cases has been related to oral contraceptives, pregnancy and puerperium, In this clinical setting prognosis is worse and renal replacement therapy is usually needed. Different authors agree that plamapheresis is the treatment of choice, and has improved patient survival to 80-90%. We describe a case of a young woman that 10 days postpartum developed thrombocytopenia, microangiopathic hemolytic anemia and acute renal failure with nephrotic range proteinuria. With the suspicion of HUS she was started on plasmapheresis initially stopped due to an anaphylactic reaction to plasma and finally due to hyperhidratation with acute pulmonary edema needing mechanical ventilation. Renal biopsy confirmed the diagnosis. Clinical course was complicated with refractory hypertension and infectious complications In conclusion postpartum HUS is a rare clinical entity , that forces a differential diagnosis with hypertensive complications of pregnancy. It is associated to multiple complications difficult to handle during follow-up. Plasmapheresis treatment adds complexity to clinical care but is the only treatment of proven efficacy in order to improve survival and renal prognosis.

Published
2008

21. [Gastric phytobezoar in a diabetic patient].

Author

Masa Vázquez C, Frieyro Segui E, Bouza Santiago E, and Martinez López de Letona J

Subjects
Gastrointestinal Motility, Humans, Male, Middle Aged, Radiography, Bezoars diagnostic imaging, Diabetes Mellitus diagnostic imaging, Stomach Diseases diagnostic imaging
Published
1978

22. [Systemic lupus erythematosus associated with nocardiosis].

Author

Pina Boronat R, López de Letona JM, Frieyro Segui E, Masa Vázquez C, Bouza Santiago E, Pérez Maestu R, Damaso D, and Buzón Rueda LM

Subjects
Humans, Lupus Erythematosus, Systemic complications, Male, Middle Aged, Nocardia Infections complications, Radiography, Lupus Erythematosus, Systemic diagnostic imaging, Nocardia Infections diagnostic imaging
Published
1978

23. [Intraluminal duodenal diverticulum. Apropos of a case].

Author

Masa Vázquez C, Wert Ortega R, Ramos González L, Marcos López J, Frieyro Segui E, Pérez Maestu R, and Fernández Sedano L

Subjects
Adult, Diverticulum complications, Duodenal Diseases complications, Duodenal Obstruction diagnostic imaging, Duodenal Obstruction etiology, Humans, Male, Radiography, Diverticulum diagnostic imaging, Duodenal Diseases diagnostic imaging
Published
1980

24. [Multiple familial exostoses. Apropos of 16 cases].

Author

Guerrero Espejo A, Alonso Alonso JJ, Martińez López de Letona J, Frieyro Segui E, Bouza Santiago E, Masa Vázquez C, Pérez Maestu R, Buzón Rueda L, and Alamo Antúnez A

Subjects
Adult, Exostoses, Multiple Hereditary diagnostic imaging, Humans, Male, Pedigree, Radiography, Exostoses, Multiple Hereditary genetics
Published
1978

Catalog

Books, media, physical & digital resources
See catalog results